Case 1:09-md-02067-NMG Document 687-35 Filed 02/28/17 Page 2 of 10 MDL-FORP0017526
lIr;~ _~-. IY1S~ ~"' ~ U. _CrMI CW _ trc."'Ia' _~ ta'fI~_.,. Profes~ l"~_~"'IOIO1t.1l1oc tJgI:t.~ ._IOd_~ ~ o.:k~"' ~."'_.,.",~.-.ka ~ k~ ( 'f~'IP'-'~ Case 1:09-md-02067-NMG Document 687-35 Filed 02/28/17 Page 3 of 10 Explore the Latest Information with Our Distinguished Faculty· Program Chair Karen D. Wagner . M.D., Ph.D. Clilrence RoiS Mi lle r Professor & ViCe (hatfman Departmem 01 Psydu.)try & Behavooral ~.enc~ One(101'. DrvISIOO of Child & Ad olescent Psychiatry lJn;lIt'f\olty 01 Texas M«!tr.l18'illlrh faculty Boris Birmaher. M.D. P :cf esso r of ~y(tl .. try Un ; ve rS l iyof 1'11tslJ.ur9-'l Jam es T. Mc Cracken. M.D. Professor 01 PsydMtry n.re<:tOt. (l>Ild & AdcWs<ent D UCLA NeVl'opsydtlatnc Inst Itute 8. ~lai Neal D. Ry an. M.D. I'fofessor of Psych i <HrY J ooqulm Ptug-Anllch PrOfl:">5Of III (ho . 1d and Adolescent Psydllillry Universrty of Pittsburgh Elizabeth B. Weller. M.D. of PsydHc1Uy ¥1d Pedi.Jt rn Urnvcrs.ty 01 Pef'll'lsy'val'lla ... -. Ib • ..,.-.. ... N<fO poogo_ ...-,.,.. ''"' ..... ~ bt _ ....... ..... _ ... _c."~Uo!aI_101f\1 ..... ~_ ... OOII ... ~\ _ .. _ cw -= doso;NIs"_~ '0." flc.ocrJ I ~ 10<._01' D.IIII' *"."_ • t:..:.I"lI!IiIIW _ ___ __ "",- _ _ O/!lallr __ _ T .. _ 'cr ____ .. ."... __ 1 .................. __ I00;l00_ .... _ _ ___ .. ____ CMl.1IC._ ..... , .... Iit~ .. . CKrc._ ... _.,..,.,.. CM. . 1lI< Milf",~1oc ...... '_100." ..... MDL-FORP0017531
:, , ms I;'J t. Case 1:09-md-02067-NMG Document 687-35 Filed 02/28/17 Page 4 of 10 A Closer Look at Identifying Depression in Children and Adolescents 4 Hours Category 1 Series Chair Karen O. Wagne r, M. D., ph.D. Clarence Ross Miller Professor' & Vice Chairman Department of Psychiatry & Behavioral Sciences Director, Division of Child & Adolescent Psychiatry Univel"$ity of T ex;:t s Medical Branch, Galveston Ser i es Faculty - Boris Birmaher, M.D. Professor of Psychiatry, Uni versity of Pittsburgh Director, Child Mood Disorders Research Western Psychiatric Institute and Clinic James T. McCra cke n, M.D. Professor of Psychiatry Director. Child & Adolescent Division UCLA Neuropsychiat ric Institute & Hospital Neal O. Ryan. M.D. Joaquim Puig-Antich Professor in Child and Adolescent Psychiatry University of Pittsburgh Elizabeth B. Weller, M.D. Professor of Psychiatry and Pediatrics University of Pennsylvania Objective B y actively participating in this course, anendees will understand the prevalen<:e, signs anC: S}~ of pediatridadole sce nt depression and treatment options. Agenda 8:00·8: 30 a.m . Registration/Contine n tal Breakfast 8:30-10:00 a.m. How to Appt'opI'iately Di~noH t>.pression in Children 10 :00-10 :2 0 a. m. Question-and-Answer Session 10 :20-10:40 a.m. Break 10:40 a.m .- 12:10 p.m. Depression in Otlldren and Maximize How to »Nt TIM;, QcM/ity of Life 12 :10-12:30 p.m. Question -a nd -Ans wer Session FACULTY DISCLOSURE STATEMENTS Boris Birmaher , M.D ., has Irdca ted that he has no relationships to disdose relating to the subject matter 01 tis presentation. James T. McCracken, M.D ., has received grants ar4'Of research support lrom Sotvay Phatmaceuticals Inc., Shire Richwood, Inc .• Gliatech and Eli Lity and Company. He has also received nonorana !rom Shire Richwood, Inc., and Solvay Pharmaceuticals Inc . Neal D. Ryan, M.D., is a COOGUttant lor Pfizer Inc ., Abbott labooltories. Hoffman-La R oche Inc., and AstraZeneca Pharmaceuticals LP. He has received grants and reS&afCh support from GIaxOStnlthKllne and wyeth Ayem Pharmaceutical&. Karoo D. Wagner, 104 .0, Ph .D., receives gants and rosearctl support from and is a consultant and a member of !he AlJvisay Board for GlaxoSrMhlOine, PIzer Inc ., Forest PhatmaceoticaIs, Inc. and Abbott Labof'atories. She also S6IV8S as a consultant lor Jansseo PharmacetJtica Products, L. P. BristoI-Myers Squibb, (.)benri::s and Eli Lilly and Company and is a member 01 the Advisory Board lot Novartis PharmaceuticaI& She eIso roceiv8sgrants end researd'l support from Eli Uly and Company , BlisllJl ,tyefs SqulD. Organon Inc. a'Id WyfIitJ ~ She is a memberoflle Speskan Bureau b G 1 a:ccS i1iitl oKJine, Abbott Labotaloiies, Eli UIIy and~ Pfizer Inc. end Janssen PtwmaoeutIca Products, LP: Weier , M.D., has reo&iYed honoraria. grants and research support from and serves as a OOI'ISUtant lor NIMH, BiZabeth B. ... GlaxoSmithKtne, 0rgM0n Inc ., Abbott laboratories . ~Ayerst PhatmaceuIicaIs, Forest Pharmaceutic:als, Inc. , and Jotnson & """" , . • Supported by an unrestricted educ..-tionar grant from Forest Pharmaceuticals. Inc. K *Not all speakers will appear at each program. Facul ty subject to change without notice. MDL-FORPOO17536
slgn~lcant Case 1:09-md-02067-NMG Document 687-35 Filed 02/28/17 Page 5 of 10 Abstract How to Treat Depression in Children and Maximize Their Quality of Life Treatment for depression in children and adolescents includes psychotherapy an d pharmacotherapy . The major forms of psychotherapy being studied in adolescents are interpersonal psychotherapy and cognitive behavior therapy. In an open trial, interpersonal therapy showed reduction In adolescents' symptoms of depression. Cognttive behavior therapy has been shown to be effective in treating depression in adolescents. With regard to medications, the selective serotonin reuptake inhibitors (SS Als ) including citaJopram, fluoxetine, paroxetine and sertraline have s hown significant reduction in depression in youths compared to placebo . Side effects experienced by children and adolescents on SSRls in these trials have been mild, with the most common being nausea , stomachaches and headaches . Other antidepressants, such as nefazodone, ve nlafaxine, mirtazapine and bupropion require more controlled study in children and adolescents. Therefore, first- l ine medicat io n treatment for children and adolescents are SSAls. H a child fails to respond to one SSRI, then an alternate SSAI can be considered. If there continues to be no response, then altemative monotherapy such as bupropion , mi rtazap ine, nefazodone or venlafaxine can be initiated or augmentation strategies, such as buspirone, lithium or combination antidepressants. There are ongoing NIMH trials comparing SSRI, cognitive behavior therapy and combination treatment (SSRI plus cognitive behavior therapy) in the treatment of adolescent depression. There is also an ongoing NIMH study for treatment-resistant depression in adolescents-with the aim of determining whether a different SSRI, different class of agent or addit i on of cognitive behavior therapy improves treatment response in depressed adolescents . _ Outline_ I. Psychotherapy A. Interpersonal psychotherapy B. Cognitive behavior therapy II. Pharmacotherapy A. Selective serotonin reuptake inhibitors (SSRls ) 1. Citalopram 2. Fluo xeti ne 3. Paroxetine 4. Sertraline B. Venlafaxine C. Nefazodone D. Bupropton III. Combination Treatment (Psychotherapy Plus Medication) 20 A C loser Look at I de ntifying Depression in Children and Adolescents MDL-FORP0017555
Recommend
More recommend
